Serum ALT is well known to be a marker of NAFLD in obese individuals without other identifiable causes for liver disease to the extent that it can be added to the US as a criterion for the diagnosis of NASH [31, 32]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.